Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty

Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty

In a randomized, double-blind trial, BMD of the operated proximal femur after total hip replacement measured by dual-energy x-ray absorptiometry (DXA) were compared for up to two years in patients receiving IV ZOL 5 mg infusion (n = 27) or placebo (IV saline infusion; n = 24) at two weeks and one year after surgery.

Inclusion Criteria:

• Patients undergoing primary elective total hip replacement

Exclusion Criteria:

• Osteoporosis (BMD ≤-2.5)
• Trauma to the operated femur, hip revisions, femoral dysplasia, trochanteric osteotomy, inflammatory arthritis
• Severe renal impairment
• Use of any medications affecting BMD
• Known sensitivity to bisphosphonates
• Severe dental problems, and pregnancy or being able to conceive and not using reliable birth control methods